Pyridine cGAS Inhibitors With N-Linked Cycles for Cellular Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cGAS inhibitors exhibit insufficient cellular inhibitory potency and selectivity, leading to potential off-target effects and cytotoxicity, which hampers their therapeutic efficacy in treating autoimmune diseases.
Innovation Solution
Development of pyridine derivatives with N-linked cyclic substituents that demonstrate high biochemical and cellular inhibitory potency (IC50 ≤100 nM, THP1 IC50(vir) ≤1 μM) and selectivity (THP1 IC50(cGAMP)/THP1 IC50(vir) ≥10, effectively inhibiting cGAS activity while minimizing off-target effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing cGAS inhibitors are used, then biochemical inhibitory activity is achieved, but cellular inhibitory potency is insufficient
Solution Approach 1:
The patent applies parameter changes by systematically modifying molecular parameters of cGAS inhibitors, specifically introducing N-linked cyclic substituents at the pyridine 4-position and optimizing substituent patterns. These structural parameter changes result in compounds with IC50 values ≤100 nM in cellular assays, resolving the contradiction between biochemical activity and cellular potency.
2Measurement precision
If existing cGAS inhibitors are used, then inhibitory activity is achieved, but selectivity is insufficient leading to off-target effects
Solution Approach 1:
The patent applies local quality by introducing specific N-linked cyclic substituents at the 4-position of the pyridine ring, creating a localized structural feature that enhances selectivity. This local modification allows the compound to distinguish between cGAS and other targets, reducing off-target effects while maintaining inhibitory activity.
Solution Approach 2:
The patent modifies molecular parameters by optimizing the cyclic substituent structure (sizes 3-7 membered rings with specific heteroatoms) and substitution patterns, achieving selectivity ratios (THP1 IC50(cGAMP)/THP1 IC50(vir)) ≥10, thereby resolving the contradiction between activity and selectivity.
3Measurement precision
If existing cGAS inhibitors are used, then inhibitory potency is achieved, but cytotoxicity occurs
Solution Approach 1:
The patent applies parameter changes by optimizing the balance between hydrophobic and hydrophilic characteristics through the selection of cyclic substituents with specific heteroatoms (N, O, S) and substitution patterns. This results in compounds with high inhibitory potency (IC50 ≤100 nM) that maintain favorable safety profiles by reducing cytotoxicity.
Data Source
AI summary
The invention relates to new proline derivatives of formula (I) as cGAS inhibitors,whereinwherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and G are defined as in claim 1, and prodrugs or pharmaceutically acceptable salts of these compoundsfor the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), non alcoholic steatotic hepatitis (NASH), interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF).